Abstract: OBJECTIVE To analyze the relationship between cervical high-risk HPV infection and genital infection, as well as the detection value of HPV DNA. METHODS 967 patients with various gynecological diseases treated in our hospital from Oct. 2016 to Oct. 2017 were selected as the study subjects. Patients were given corresponding inspection after admission, and the case number of genital infection was recorded. The exfoliated cells from cervical outlet and cervical canal of all high-risk HPV patients were collected and tested by hybridization capture and thin layer liquid based cell test. The detailed test results were recorded and the correlation and detection value were analyzed. RESULTS In the 967 patients, a total of 469 cases of genital infections were detected, accounting for 48.50%. A total of 373 cases of high-risk HPV infection were detected, accounting for 38.57%.In the 469 cases of patients with genital infections, 236 were detected with high-risk HPV infection, accounting for 50.32%, and the genital infections were dominated by vulvovaginal candida infection. 498 cases of patients were not detected with genital infections, accounting for 51.50%, among which 127 cases of high-risk HPV infection were detected accounting for 25.50%. Multivariate logistic regression analysis showed that vulvovaginal Candida, recurrent vulvovaginal Candida, trichomoniasis vaginitis, and Chlamydia trachomatis were the risk factors of genital infection and high-risk HPV infection (P<0.05). Pathological biopsy detected a total of 105 patients with CIN, and 3 patients with cervical cancer. In the 108 patients with CIN and cervical cancer, 74 patients were detected with high-risk HPV infection, and the HPV infection rate was 68.52%. CONCLUSION The high-risk HPV positive infection rate is also higher in people with higher genital infection rate. The incidence of infection is positively correlated. The effective detection of HPV positive infection rate can predict the development of patients' condition, and provide data for follow-up treatment of patients with CIN and cervical cancer.